761 Stock Chart & Stats
€80.60
-€0.50(-0.61%)
At close: 4:00 PM EDT
€80.60
-€0.50(-0.61%)
Day’s Range― - ―
52-Week Range€38.55 - €94.00
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€714.46M
Enterprise Value€842.83
Total Cash (Recent Filing)€29.00M
Total Debt (Recent Filing)€19.10M
Price to Earnings (P/E)34.8
Beta0.39
Next Earnings
Nov 09, 2026EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.22
Shares Outstanding9,680,977
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€97.00Price Target Upside20.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.59
Revenue Forecast (FY)€156.10M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue has more than doubled since 2021 and continued growing into the latest trailing period, demonstrating sustained demand for PharmaNutra’s products. This expanding scale can support broader commercialization, operating investment, and stronger long-term earnings potential if profitability stabilizes.
Improving Balance SheetDebt reduction alongside steadily rising equity strengthens financial resilience and reduces dependence on borrowing to support operations or growth. Moderate leverage provides greater flexibility for product development, international expansion, and absorbing periods of weaker operating performance.
Positive Cash GenerationConsistently positive operating cash flow and solid recent free cash flow indicate that the business is converting its commercial activity into funding internally. This supports ongoing investment and financial flexibility without relying entirely on external capital, despite some historical volatility.
Bears Say
Operating Profitability DeteriorationThe shift to negative TTM operating profit and EBITDA raises concern about the quality and durability of reported earnings. If the weakness persists, it could limit reinvestment capacity, reduce the benefit of revenue growth, and cause historically strong returns to moderate.
Volatile Free Cash Flow ConversionAlthough recent cash generation is healthy, the history of negative free cash flow and less-than-complete conversion from net income indicates uneven funding capacity. Continued volatility could make investment planning less predictable and reduce the buffer available during weaker operating periods.
Uncertain Margin DurabilityVolatile gross margins and the sharp latest-period deterioration in operating performance make future profitability harder to forecast. This uncertainty may weaken the earnings contribution from incremental revenue and complicate decisions on product expansion, marketing, and other growth investments.
PharmaNutra SpA News
761 FAQ
What was PharmaNutra SpA’s price range in the past 12 months?
PharmaNutra SpA lowest stock price was €38.55 and its highest was €94.00 in the past 12 months.
What is PharmaNutra SpA’s market cap?
PharmaNutra SpA’s market cap is €714.46M.
When is PharmaNutra SpA’s upcoming earnings report date?
PharmaNutra SpA’s upcoming earnings report date is Nov 09, 2026 which is in 53 days.
How were PharmaNutra SpA’s earnings last quarter?
PharmaNutra SpA released its earnings results on Sep 11, 2026. The company reported €0.67 earnings per share for the quarter.
Is PharmaNutra SpA overvalued?
According to Wall Street analysts PharmaNutra SpA’s price is currently Undervalued.
Does PharmaNutra SpA pay dividends?
PharmaNutra SpA does not currently pay dividends.
What is PharmaNutra SpA’s EPS estimate?
PharmaNutra SpA’s EPS estimate is 0.83.
How many shares outstanding does PharmaNutra SpA have?
PharmaNutra SpA has 9,680,977 shares outstanding.
What happened to PharmaNutra SpA’s price movement after its last earnings report?
PharmaNutra SpA reported an EPS of €0.67 in its last earnings report. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of PharmaNutra SpA?
Currently, no hedge funds are holding shares in DE:761
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaNutra SpA
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
761 Stock 12 Month Forecast
Average Price Target
€97.00
▲(20.35% Upside)
Technical Analysis
Garofalo Health Care S.P.A.
―
Arterra Bioscience SpA
―
Eukedos S.p.A.
―
Farmacosmo S.P.A.
―
Svas Biosana S.p.A.
―